Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice

Figure 3

Lobeglitazone treatment reduces serum cholesterol and triglyceride (TG) levels in HFD-fed mice. Serum concentrations of lipid were measured after 12 weeks of a HFD or NCD. (a) Serum total cholesterol level. (b) Serum high density lipoprotein (HDL) cholesterol level. (c) Serum low density lipoprotein (LDL) cholesterol level. (d) Serum TG level. (e) Alanine aminotransferase (ALT) level. (f) Aspartate aminotransferase (ALP) level. NU: normal chow diet- (NCD-) fed mice without treatment (NU, black bar), HU: HFD-fed mice without treatment (white bar), and HL: HFD-fed mice with lobeglitazone treatment (gray bar). Data are expressed as means ± SEM. p < 0.05, p < 0.001, and p < 0.0001, NU versus. HU group. ^#p < 0.05, ^##p < 0.001, and ^###p < 0.0001, HL versus. HU group.

(a)

(b)

(c)

(d)

(e)

(f)